ArticleJournal of comparative effectiveness research2025

A comparison of healthcare resource utilization and costs between patients with chronic lymphocytic leukemia treated with first-line ibrutinib or acalabrutinib using two large US real-world databases.

Kerry A Rogers et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.